Formulation Development & Drug Delivery In-Depth Focus 2017
Posted: 22 February 2017 | European Pharmaceutical Review | No comments yet
Understanding the effect of API changes in pharmaceutical processing; Improving the consistency of MDI drug delivery; and Expert Views with DDF Summit and Eurofins Lancaster Laboratories…
- Understanding the effect of API changes in pharmaceutical processing
John Gamble, John Jones and Mike Tobyn, Bristol-Myers Squibb - Improving the consistency of MDI drug delivery
David Lewis, Chiesi Ltd - Expert View
With DDF Summit - Expert View
With Eurofins Lancaster Laboratories
This Formulation Development & Drug Delivery In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Issue
Related topics
Related organisations
Bristol-Myers Squibb Company, Capsugel, Chiesi Ltd, Eurofins
